Fig. 5

Overexpression or inhibition of miR-644a on cell migration, invasion and DOX resistance in MDA-MB-231. CCR7 is a target gene of miR-644a. A Colony formation assay with altered miR-644a expression. B Wound healing assay for cell migration with miR-644a mimic or miR-644a inhibitor or with respective controls. C Transwell assay for cell invasion with altered miR-644a expression. D CCK8 assay for cell viability and IC50 with altered miR-644a expression. E Venn diagram showed the predicted target genes of miR-644a from TargetScan7, miRDB and miRTarBase.The predicted binding sites of miR-644a and CCR7. F CCR7 expression in breast cancer tissues as compared to the noncancerous breast tissues from TCGA. G CCR7 expression in breast cancer tissues of different molecular subtypes from TCGA. H CCR7 expression in tumor tissues of breast cancer patients with different stages from TCGA. I and J Luciferase reporter assay in HEK-293T cotransfected with pRL-TK carrying wildtype or mutant binding site of 3′UTR of CCR7 and the miR-644a mimic or the miR-644a inhibitor, and the luciferase activity was measured 48 h posttransfection. K Western blot assay of the expression of ABCB1, E-cadherin, Vimentin, VEGF, CCR7, p-ERK, ERK, p-p38 and p38 with altered miR-644a expression. L Western blot assay of the expression of CCR7, p-ERK, ERK, p-p38 and p38. Results were presented as mean ± SD of three independent experiments. *P < 0.05, *P < 0.01, and  ***P < 0.001